Wat zijn de openingstijden?

Maandag 09:00 - 17:00 Dinsdag 09:00 - 17:00 Woensdag 09:00 - 17:00 Donderdag 09:00 - 17:00 Vrijdag 09:00 - 17:00

HemoClear

Red Blood Cell Filter enabling autologous blood transfusion

23/10/2025

In “Guidance on Implementing Patient Blood Management to Improve Global Blood Health Status”, the World Health Organization calls for practical strategies to reduce dependence on donor blood.

The WHO cites HemoClear® as part of the autologous transfusion management toolkit.
The HemoClear gravity-driven blood filter enables high-quality bedside autotransfusion, offering a portable solution for hospitals, emergency response teams, and rural clinics.

🩸 No electricity, no infrastructure, just a system-ready innovation that aligns with WHO’s call for resilient, resource-appropriate blood management.

🌐https://www.hemoclear.com/

21/10/2025

🩸 What Happens to the 500–700 mL of blood left in ECMO circuits?

Too often, it's:
🔴Reinfused, risking inflammatory mediators
🔴Cell salvaged, adding cost and damaging platelets
🔴Discarded, increasing donor blood dependence

🔘 HemoClear enables bedside reinfusion of platelet-rich autologous blood — without complex equipment.

From ECMO weaning to postoperative care, HemoClear supports Patient Blood Management by conserving the patient’s own blood, maximizing autologous use and minimizing reliance on donor supply.

🌐 https://www.hemoclear.com/

16/10/2025

☕️Caffeine, a non-selective antagonist of the ADORA2B receptor found on red blood cells (RBCs), appears to interfere with key metabolic and hypoxic responses, including glycolysis and 2,3-BPG synthesis, both essential for oxygen delivery under stress.

These findings suggest that caffeine may compromise ATP production and increase hemolysis during storage.

💡 Why This Matters for Innovation in Blood Transfusion

By enabling autologous blood recovery and bedside reinfusion, HemoClear supports PBM strategies that eliminate the need for extended storage, thereby avoiding biochemical degradation risks linked to factors like caffeine exposure.

As we deepen our understanding of how lifestyle and genetics influence transfusion outcomes, it's also time to rethink how we approach blood safety, quality, and innovation.

🌐https://www.hemoclear.com/

14/10/2025

A recent simulation of a large-scale conflict revealed:

🔴80,000–150,000 casualties in the first 2 weeks
🔴Up to 600,000 liters of blood required
🔴Critical shortages of red cells, plasma, and platelets

For defense health systems, these numbers are more than statistics, they are a strategic warning.
When conventional blood supply systems break down, we need solutions that move with the mission.

👉HemoClear: Tactical readiness in a box

HemoClear is a field-ready, microfiltration device that enables autologous blood transfusion:

✅ No cold chain, electricity, or infrastructure required
✅ Operable with minimal training
✅ Enhances self-sufficiency and reduces reliance on external blood logistics

This is not just innovation, it’s operational readiness.

🌐https://www.hemoclear.com/

09/10/2025

A life-saving shift in rural South Africa

Across rural Africa, a quiet revolution is taking place, one that’s saving lives and strengthening communities.

This short video tells a powerful story of how autologous blood transfusion is transforming maternal healthcare in low-resource settings. In areas where donor blood is scarce, HemoClear’s autologous bloodtransfusion is bridging critical gaps with a low-tech, high-impact solution.

Local healthcare teams are adopting HemoClear, proving that meaningful change is both possible and scalable.

This is more than a clinical success. It’s a community impact story, and it deserves the attention of healthcare professionals and policymakers seeking sustainable solutions in under-resourced environments.

Watch the story. Share to amplify. Inspire change.

https://www.hemoclear.com/

24/07/2025

Cell Salvage process optimization drives quality

An analysis of 238 centrifugal cell salvage procedures (154 men, 84 women) demonstrated that quality control benchmarks were consistently achieved, reinforcing the reliability of autologous transfusion in surgical care.

Nevertheless, some variability was observed:
🔴Hematocrit targets were not met in 22% of cases
🔴Total protein elimination was insufficient in 8%

Patient-specific factors, such as age, gender, and surgical indication, had minimal impact on these outcomes.

Instead, variability was driven in nonemergency cases, by technical and procedural conditions, such as:
🔵 Low collection volumes
🔵 Excessive dilution with irrigation fluids

Anesthesiologists play a pivotal role in ensuring the quality of autologous transfusion. With real-time awareness, they adapt collection and wash parameters, even in complex or suboptimal surgical conditions, to uphold transfusion standards and protect patient outcomes.

Curious to test microfiltration technology under similar conditions, independent of centrifugal systems?

✉️ Contact us at info@https://bit.ly/419jNT1
🌐 Visit https://bit.ly/419jNT1
📑 Reference: https://bit.ly/4lPn56q

22/07/2025

Advancing Intraoperative Blood Management in Spine Surgery

In Adult Spine Deformity (ASD) surgery, where intraoperative blood loss is often significant, cell salvage plays a critical role in reducing reliance on allogenic transfusions and improving perioperative outcomes.

Key clinical and economic advantages include:
✅ Reduction in allogenic transfusion rates by 18–33%
✅ Preservation of 0.3–1 unit of donor blood per patient, when transfusion is still required
✅ Greatest efficacy observed in procedures with blood loss ≥15 mL/kg
✅ Potential cost savings up to $422 per case

Hemoclear introduces a novel solution, a straightforward, single-use microfiltration system that enables broader access to platelet-rich autologous blood reinfusion. By eliminating the complexity of conventional systems, Hemoclear offers an adaptable and cost-effective approach to intraoperative blood recovery.

Learn more: info@hemoclear.com | 🌐 https://bit.ly/3Ck6OB9

17/07/2025

Can safe and efficient blood recovery be achieved during C-sections in low-resource settings?
A newly published study in the International Journal of Gynecology & Obstetrics offers a resounding yes.

Researchers evaluated the HemoClear microfiltration system in cesarean sections at a South African tertiary hospital, and the results are compelling.

Key findings and clinical highlights
🩸75.5% erythrocyte recovery, with strong platelet retention
🩸Safe bacterial profile and >75% removal of α-fetoprotein, supporting reinfusion safety
🩸No electricity, centrifuge, or costly equipment needed
🩸Filtration completed in ~15 minutes, making it workflow-compatible

The authors conclude that HemoClear could significantly enhance obstetric care in LMICs, where blood shortages and transfusion risks are prevalent. This gravity-driven solution offers affordable, portable, and practical cell salvage, exactly where it's needed most.

📄 Full article: https://bit.ly/4eUteeD

15/07/2025

HemoClear aligns with all five strategic goals of the EU’s Stockpiling and Medical Countermeasures Strategies, directly supporting Europe's crisis readiness and health security.

1️⃣ Threat Intelligence & Early Response
Our equipment and electricity free autologous blood transfusion solution enhances clinical resilience in disaster zones and outbreak scenarios.

2️⃣ Accelerating Medical Countermeasures (MCM)
By enabling donation-independent blood transfusion and positioning convalescent plasma as a frontline treatment in future pandemics, HemoClear provides a scalable and innovative approach to lifesaving interventions.

3️⃣Agile Manufacturing
HemoClear is manufacturing-ready for rapid scale-up and partnerships.

4️⃣Stockpiling & Procurement
As a non-perishable, storable device, it fits perfectly into joint procurement strategies for future readiness.

5️⃣Civilian-Military Coordination & Training
Versatile across sectors, HemoClear builds capacity and empowers decentralised preparedness through a straightforward blood processing procedure.

One innovation, five strategic impacts.

19/06/2025

Join us at the Combat Medical Care Conference 2025 in Ulm, Germany.

HemoClear is proud to participate in the SOF Workshop on July 1st, held on the occasion of the 2025 Combat Medical Care Conference, the international symposium on Tactical Combat Casualty Care for medics, EMTs, paramedics, nurses, and physicians operating in military and law enforcement missions.

We look forward to connecting with frontline professionals to explore the role of autologous blood transfusion even in Role I settings, where conventional cell savers and electricity are unavailable.

HemoClear’s gravity-driven blood filtration system offers a unique solution to treat severe bleeding in austere environments.

17/06/2025

New Publication Alert

In a recently published case report, we explore the successful treatment of myasthenia gravis (MG) following long COVID in a 71-year-old patient, using HemoClear gravity-driven plasma exchange.

Despite initial deterioration and resistance to standard therapy, the patient showed marked clinical improvement following low-volume plasmapheresis using HemoClear’s straightforward and cost-effective gravity-driven microfiltration technology.

This case highlights the value of accessible innovations like HemoClear in managing complex post-COVID autoimmune conditions, where conventional treatments may be unavailable.

Read the full case: https://bit.ly/3Hxwr7m
Efficacy of Plasma Exchange in Myasthenia Gravis Following Long COVID in a Resource-Limited Context

12/06/2025

What if patients didn’t have to rely on others for life-saving blood?

With breakthrough cell salvage technology like HemoClear, patients can receive their own freshly micro-filtered blood, right in the OR or recovery room. No machines, no electricity, no donor blood needed.

HemoClear empowers clinicians to deliver:
🔹Platelet-rich transfusion blood.
🔹100% biologically compatible transfusions
🔹 Ultra-low risk of transfusion-related infections or immune reactions
🔹 Simpler workflows, no crossmatch or complex logistics
🔹 Patient's independence from donor systems

This next-generation patient blood management makes blood transfusion safer, smarter, and sustainable.

Check out how: https://www.hemoclear.com/

Adres

Dokter Stolteweg 70A
Zwolle
8025AZ

Openingstijden

Maandag	09:00 - 17:00
Dinsdag	09:00 - 17:00
Woensdag	09:00 - 17:00
Donderdag	09:00 - 17:00
Vrijdag	09:00 - 17:00

Telefoon

+31383032630

Website

http://hemoclear.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer HemoClear nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.